Pharmacology, Toxicology and Pharmaceutical Science
Low Density Lipoprotein Cholesterol
100%
Familial Hypercholesterolemia
84%
Bempedoic Acid
46%
Lipoprotein
39%
Statin (Protein)
36%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
33%
Placebo
31%
Coronary Artery Atherosclerosis
29%
Evinacumab
26%
Cerebrotendinous Xanthomatosis
25%
Clinical Trial
25%
Triacylglycerol
24%
Cardiovascular Disease
21%
Proprotein Convertase 9
21%
Disease
19%
Lipoprotein A
18%
Atherosclerosis
18%
Dyslipidemia
18%
Low Density Lipoprotein
17%
Pancreatitis
16%
Mipomersen
15%
Syndrome
14%
Adverse Event
14%
Chenodeoxycholic Acid
13%
Acute Pancreatitis
11%
Folic Acid
11%
Homocysteine
11%
Tolerability
10%
Dietary Antioxidant
10%
Alirocumab
10%
C Reactive Protein
9%
Cardiovascular Risk
9%
Vascular Disease
8%
Pyridoxine
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Symptom
8%
CYP27A1
8%
Low Density Lipoprotein Receptor
7%
Apolipoprotein B
7%
Lomitapide
7%
Hypercholesterolemia
7%
Monoclonal Antibody
7%
Ezetimibe
7%
Bile Acid
6%
Vitamin B12
6%
Hypertriglyceridemia
6%
Side Effect
6%
Ischemic Heart Disease
6%
Non Insulin Dependent Diabetes Mellitus
6%
Impaired Glucose Tolerance
6%
Medicine and Dentistry
Familial Hypercholesterolemia
66%
Low Density Lipoprotein Cholesterol
61%
Cerebrotendinous Xanthomatosis
46%
Statin
28%
Preventive Cardiology
27%
Chylomicronemia
26%
Bempedoic Acid
25%
Disease
25%
Drug Therapy
21%
Clinical Trial
20%
Lipoprotein
20%
Chenodeoxycholic Acid
18%
Dyslipidemia
18%
Cardiovascular System
16%
Triacylglycerol
15%
Prevalence
15%
Evinacumab
15%
Lipoprotein Apheresis
15%
Cardiovascular Disease
14%
Cataract
13%
Hypercholesterolemia
13%
Cardiovascular Risk
13%
Placebo
13%
Awareness
13%
Low-Density Lipoprotein
12%
Diabetes
12%
Cholestanol
12%
Maturity Onset Diabetes of the Young
11%
Atherosclerosis
10%
Diagnosis
10%
Medicine
10%
Glycemic Control
10%
Pancreatitis
10%
Lipid Diet
9%
Early Diagnosis
9%
Symptom
9%
Bile Acid
9%
Acute Pancreatitis
8%
Patient with Type 2 Diabetes
8%
Low Fat Diet
8%
Combination Therapy
8%
Bile
8%
LDL Receptor
7%
Pathophysiology
7%
Fat Intake
7%
Pyridoxine
7%
Xanthoma
6%
Ezetimibe
6%
Proprotein Convertase 9
6%
Health Care Cost
6%
Keyphrases
Homozygous Familial Hypercholesterolemia (HoFH)
45%
Low-density Lipoprotein Cholesterol (LDL-C)
37%
Atherosclerotic Cardiovascular Disease (ASCVD)
31%
Cerebrotendinous Xanthomatosis
25%
Bempedoic Acid
25%
Scientific Statement
25%
Statins
23%
National Lipid Association
18%
Low-density Lipoprotein Cholesterol Goal
17%
Chylomicronemia
16%
High-density Lipoprotein Cholesterol (HDL-C)
14%
Lipoproteins
14%
Cardiovascular Risk
13%
PCSK9 Inhibitors
12%
Low-density Lipoprotein
12%
Dyslipidemia
12%
Lipids
12%
Chenodeoxycholic Acid
12%
Phase III Clinical Trial
11%
Evinacumab
11%
Ezetimibe
10%
Non-enzymatic Glycation
10%
Mipomersen
10%
Dietary Antioxidants
10%
Expert Consensus Statement
10%
Pathophysiology
9%
Low-density Lipoprotein Receptor
9%
Treatment during Pregnancy
9%
India
9%
Acid Treatment
8%
Cholestanol
8%
Juvenile Cataract
7%
United States
7%
Rare Disorders
7%
Risk Factors
7%
Triglycerides
7%
High-sensitivity C-reactive Protein (hs-CRP)
7%
Goal Attainment
7%
Adverse Events
6%
Homocysteine
6%
Plasma Lipoproteins
6%
Cardiovascular Outcomes
6%
Hypertriglyceridemia
6%
Lomitapide
6%
Placebo
6%
Lipoprotein Apheresis
6%
Type 2 Diabetes Mellitus (T2DM)
6%
Weight Loss
6%
Dietary Modification
6%
Four-phase
6%